Management of Immune-Related Rash After Opdivo and Yervoy Treatment
Critical First Steps: Rule Out Life-Threatening Conditions
- The American Society of Clinical Oncology (ASCO) recommends performing a thorough physical examination, including all mucosal surfaces, to assess for lymphadenopathy, facial/extremity swelling, pustules, blisters, erosions, and areas of dusky erythema painful to palpation 1
- Obtain laboratory workup, including complete blood count with differential and liver function tests, to rule out DRESS syndrome, Stevens-Johnson syndrome, or toxic epidermal necrolysis 2, 4
- Review biopsy results with dermatology to confirm immune-mediated dermatitis versus severe cutaneous adverse reactions (SCARs) 1
Grade-Based Treatment Algorithm
Grade 1: Rash <10% BSA
- Continue immunotherapy without interruption, as recommended by the European Society for Medical Oncology (ESMO) 1, 2, 3
- Apply topical emollients liberally multiple times daily, as suggested by the Journal of Clinical Oncology 1, 6
- Use mild-to-moderate potency topical corticosteroids to affected areas once daily, as recommended by the American College of Dermatology 1, 2
Grade 2: Rash 10-30% BSA
- Consider holding immunotherapy and monitor weekly, as recommended by the Journal of Clinical Oncology 1
- Escalate to medium-to-high potency topical corticosteroids applied twice daily, as suggested by the Annals of Oncology 1, 2, 3
- Continue topical emollients and oral antihistamines, as recommended by the ESMO 2, 3
Grade 3: Rash >30% BSA or Grade 2 with Severe Symptoms
- Hold immunotherapy immediately until rash improves to Grade 1, as recommended by the ASCO 1, 2, 3, 4
- Initiate systemic corticosteroids: oral prednisone 1 mg/kg/day, as suggested by the Journal of Clinical Oncology 1, 2, 3
- Continue high-potency topical corticosteroids, oral antihistamines, and emollients, as recommended by the Annals of Oncology 1, 2, 4
Grade 4: Skin Sloughing >30% BSA with Systemic Symptoms
- Immediately discontinue immunotherapy permanently, as recommended by the ASCO 1, 2, 3, 4
- Admit patient urgently with direct oncology and dermatology involvement, as suggested by the Journal of Clinical Oncology 1, 2
- Initiate IV methylprednisolone 1-2 mg/kg with slow tapering when toxicity resolves, as recommended by the Annals of Oncology 1, 2, 3
Monitoring and Follow-Up
- Weekly monitoring for Grade 2 rash to assess for progression, as recommended by the Journal of Clinical Oncology 1, 2
- Serial clinical photography to objectively track changes, as suggested by the Journal of Clinical Oncology 1
- Watch for signs of secondary infection, which may require systemic antibiotics, as recommended by the Praxis Medical Insights 7